


CLAIMS:

1. A peptide selected from the group having the formulae:



5 wherein X is PhAc, IndAc, Ibu, Nac, 1- or 2-Npr, or Fpr,

R<sup>1</sup> is Tyr or His,

R<sup>2</sup> is D-Arg or D-Cit,

R<sup>5</sup> is Ile or Val,

R<sup>6</sup> is Phe, Nal or Phe(Y), in which Y = F, Cl, Br,

10 R<sup>8</sup> is Asn, Gln, Ser, Thr, Ala, D-Asn, D-Gln, D-Ser, D-Thr, Abu, D-  
Abu, or Aib,

R<sup>9</sup> is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr  
(Me), Ser, Ala or Aib,

R<sup>10</sup> is Tyr or Phe(Y), in which Y = H, F, Cl, Br, or OCH<sub>3</sub>,

15 R<sup>12</sup> is Lys, D-Lys, or Orn,

R<sup>13</sup> is Val or Nle,

R<sup>14</sup> is Leu or Nle,

R<sup>15</sup> is Gly, Ala, Abu, Nle or Gln,

R<sup>16</sup> is Gln or Arg,

20 R<sup>18</sup> is Ser or Nle,

R<sup>19</sup> is Ala or Abu,

R<sup>21</sup> is Lys or Orn,

R<sup>22</sup> is Leu, Ala or Aib,

R<sup>27</sup> is Met, Leu, Nle, Abu, or D-Arg,

25 R<sup>28</sup> is Arg, D-Arg, Ser, Asn, Asp, Ala or Abu,

R<sup>29</sup> is Arg, D-Arg, Har or D-Har,

and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 selected from the group consisting of

30 [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)  
NH<sub>2</sub> Peptide 1

00149-512455

[IndAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 2

[PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 3

5 [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 6

[PhAc<sup>0</sup>, His<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 7

10 [Nac<sup>0</sup>, His<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 8

3. A compound of claim 1 having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 1

15 4. A compound of claim 1 having the formula [IndAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 2

5. A compound of claim 1 having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Har<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 3

6. A compound of claim 1 having the formula [PhAc<sup>0</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Tyr(Me)<sup>10</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 6

25

7. A compound of claim 1 having the formula [PhAc<sup>0</sup>, His<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 7

30 8. A compound of claim 1 having the formula [Nac<sup>0</sup>, His<sup>1</sup>, D-Arg<sup>2</sup>, Phe(pCl)<sup>6</sup>, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> Peptide 8

10. A method of treating a patient having a cancer carrying receptors for IGF-I or -II which comprises administering to said patient an effective amount of a compound of claim 1.

11. A method for inhibiting IGF-II levels in tumors (cancers) and the expression of mRNA for IGF-II in the same tumors, which comprises administering to said patient an effective amount of a compound of claim 1.

Sub A1